Ibio, Inc. balance sheet
At the end of fiscal 2026, Ibio, Inc. had total assets of $99.1m, total liabilities of $13.4m and shareholders' equity of $85.7m. It held $56.4m in cash against $0 of debt: net cash of $56.4m.
Balance sheet
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3 | 6 | 4 | 4 | 9 | 16 | 16 | 4 | 4 | 55 | 77 | 23 | 4 | 14 | 9 | 56 |
| Receivables | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | — | — |
| Inventory | — | — | — | — | — | — | — | — | — | — | 0 | 4 | 0 | 0 | — | — |
| Total current assets | 4 | 7 | 7 | 4 | 10 | 24 | 9 | 16 | 5 | 62 | 105 | 45 | 26 | 16 | 10 | 92 |
| Total assets | 7 | 10 | 9 | 6 | 12 | 52 | 36 | 43 | 31 | 94 | 147 | 99 | 41 | 29 | 23 | 99 |
| Accounts payable | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 2 | 0 | 2 | 4 |
| Deferred revenue (current) | — | — | — | — | — | — | — | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| Total current liabilities | 7 | 4 | 4 | 0 | 1 | 2 | 2 | 2 | 3 | 5 | 7 | 30 | 22 | 4 | 6 | 12 |
| Long-term debt | — | — | — | — | — | — | — | — | 0 | 0 | 0 | — | — | 1 | — | — |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | — | 13 | 1 | 1 | 0 |
| Total liabilities | — | — | — | 0 | 1 | 28 | 27 | 27 | 28 | 38 | 38 | 36 | 26 | 7 | 8 | 13 |
| Shareholders' equity | 0 | 6 | 5 | 6 | 11 | 10 | 9 | 16 | 2 | 57 | 109 | 63 | 15 | 21 | 15 | 86 |
| Non-controlling interests and other (assets − liabilities − equity) | — | — | — | — | — | 14 | — | — | — | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | −3 | −6 | −4 | −4 | −9 | −16 | −16 | −4 | −4 | −55 | −77 | −23 | 9 | −13 | −7 | −56 |
| Shares outstanding | — | — | — | — | — | — | — | — | — | — | — | — | 6m | — | 97m | 111m |
| Quarter | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | — | — | — | — | 0 | — | — | — |
| Total current assets | 12 | 8 | 6 | 10 | 51 | 53 | 77 | 92 |
| Total assets | 25 | 22 | 19 | 23 | 64 | 64 | 86 | 99 |
| Accounts payable | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 4 |
| Deferred revenue (current) | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total current liabilities | 3 | 5 | 5 | 6 | 6 | 6 | 7 | 12 |
| Long-term debt | 1 | 1 | — | — | — | — | — | — |
| Total debt | 1 | 1 | — | — | — | — | — | — |
| Total liabilities | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 13 |
| Shareholders' equity | 18 | 14 | 11 | 15 | 56 | 57 | 78 | 86 |
| Shares outstanding | 9m | 9m | 10m | 19m | 20m | 30m | 35m | 56m |
Compare with peers
- Lisata Therapeutics, Inc. balance sheet
- AIM Immunotech Inc. balance sheet
- Celldex Therapeutics, Inc. balance sheet
- Clene Inc. balance sheet
- Cervomed Inc. balance sheet
Head to head: IBIO vs LSTAAIM vs IBIOCLDX vs IBIOCLNN vs IBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies